Prostate Cancer - Results from #80

Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis. September 19, 2022

SPOP mutations as a Predictive Biomarker for Androgen Receptor-Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer. September 19, 2022

An evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction. September 19, 2022

Differential Biopsy Patterns Influence Associations Between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial. September 19, 2022

Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa. September 19, 2022

Cancer-related self-perception in men affected by prostate cancer after radical prostatectomy. September 16, 2022

Prostate cancer classification using radiomics and machine learning on mp-MRI validated using co-registered histology. September 16, 2022

Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. September 16, 2022

Late Adverse Health Outcomes and Quality of Life after curative radiotherapy + long-term ADT in Prostate Cancer Survivors: Comparison with men from the general population. September 16, 2022

Extensive Alteration of Androgen Precursor Levels after Castration in Prostate Cancer Patients and Their Association with Active Androgen Level. September 16, 2022

Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis September 15, 2022

Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients. September 15, 2022

Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer-exploratory analysis of LATITUDE study. September 15, 2022

A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer September 15, 2022

Chemosensitizing Effect and Efficacy of Wilforlide A in Combination With Docetaxel in Drug-resistant Prostate Cancer. September 15, 2022

Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy. September 15, 2022

Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. September 15, 2022

CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future. September 15, 2022

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. September 15, 2022

Antidepressant medication use and prostate cancer recurrence in men with depressive disorders. September 14, 2022

Page 5 of 1252

email news signup